

DRUG DESIGN

Edited by E. J. Ariëns

VOLUME VI



DRUG DESIGN

Edited by E. J. Ariëns

DEPARTMENT OF PHARMACOLOGY
UNIVERSITY OF NIJMEGEN
NIJMEGEN, THE NETHERLANDS

VOLUME VI



ACADEMIC PRESS New York San Francisco London 1975
A Subsidiary of Harcourt Brace Jovanovich, Publishers

COPYRIGHT © 1975, BY ACADEMIC PRESS, INC.
ALL RIGHTS RESERVED.

NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR
TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC
OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR ANY
INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT
PERMISSION IN WRITING FROM THE PUBLISHER.

ACADEMIC PRESS, INC.
111 Fifth Avenue, New York, New York 10003

United Kingdom Edition published by
ACADEMIC PRESS, INC. (LONDON) LTD.
24/28 Oval Road, London NW1

Library of Congress Cataloging in Publication Data
Main entry under title:

Drug design.

(Medicinal chemistry; a series of monographs, v. 11)

Includes bibliographies.

1. Pharmacology—Collected works. 2. Chemistry,
Medical and pharmaceutical—Collected works. I. Ariëns,
Everhardus Jacobus, ed. II. Series. [DNLM: 1. Chem-
istry. Pharmaceutical. 2. Drug Compounding.
3. Pharmacology. W1 ME64]
RM300.D74 615'.1 72-127678
ISBN 0-12-060306-3 (v. 6)

PRINTED IN THE UNITED STATES OF AMERICA

List of Contributors

Numbers in parentheses indicate the pages on which the authors' contributions begin.

- EDMUND S. COPELAND (81), Division of Biochemistry, Walter Reed Army Institute of Research, Washington, D.C.
- RAYMOND E. COUNSELL (171), College of Pharmacy, The University of Michigan, Ann Arbor, Michigan
- J. DE VRIES (1), Department of Medicinal Chemistry, Vrije Universiteit, Amsterdam, The Netherlands
- A. F. HARMS (1), Gist-Brocades N. V., Research Development, Delft, The Netherlands
- G. S. HARTLEY (297),* Chesterford Park Research Station, Fisons Pest Control Ltd., Saffron Walden, Essex, England
- HANS-JOACHIM HERMS (261), Fischersallee 49-59, Hamburg, Germany
- W. HESPE (1), Gist-Brocades N.V., Research Department, Haarlem, The Netherlands
- AKIKO HIJIKATA (143), Department of Physiology, Kobe University School of Medicine, Kusunoki-cho, Ikuta-ku, Kobe, Japan
- RODNEY D. ICE (171), College of Pharmacy, The University of Michigan, Ann Arbor, Michigan
- DANIEL L. KLAYMAN (81), Division of Medicinal Chemistry, Walter Reed Army Institute of Research, Washington, D.C.

* Present address: 57 Aurora Terrace, Hillcrest, Hamilton, New Zealand.

- W. TH. NAUTA (1), Department of Medicinal Chemistry, Vrije Universiteit, Amsterdam, The Netherlands
- SHOSUKE OKAMOTO (143), Department of Physiology, Kobe University School of Medicine, Kusunoki-cho, Ikuta-ku, Kobe, Japan
- R. F. REKKER (1), Gist-Brocades N. V., Research Department, Haarlem, and Medical Faculty, Vrije Universiteit, Amsterdam, The Netherlands
- VOLKER TAENZER (261), Klinik für Radiologie, Nuklearmedizin u. Physikalische Therapie der Freien Universität Berlin im Klinikum Steglitz, Berlin, West Germany
- H. TIMMERMAN (1), Gist-Brocades N.V., Research Development, Delft, The Netherlands

Preface

Collation and interpretation of data obtained in drug development are of primary importance in drug design. Due to the restricted distribution of much of the information obtained by industrial investigators, this is not a simple matter.

This volume offers the reader a number of chapters dealing mainly with practical approaches to the development of bioactive compounds. An extensive survey is given of the fruitful and thorough investigation of the diphenhydramine derivatives which has resulted in many new valuable drugs and is still an area from which potentially useful compounds can be obtained. Chapters on the design of antiradiation agents, of organ-imaging radiopharmaceuticals, and of X-ray contrast media will supply the reader with new views in these instructive fields of investigation. Another group of compounds holding promise for the future is proteinase inhibitors discussed in Chapter 3. In the last chapter the researcher is given information on pesticide formulation which could prove helpful in the design of new drug application forms.

In general, "excursions" of investigators working on the design of therapeutics into the "gardens" of investigators involved in the development of other types of bioactive compounds such as pesticides may lead to a fruitful cross fertilization.

E. J. ARIËNS

VOLUME II

Modulation of Pharmacokinetics by Molecular Manipulation
E. J. Ariëns

Factors in the Design of Reversible and Irreversible Enzyme Inhibitors
Howard J. Schaeffer

The Design of Organophosphate and Carbamate Inhibitors of Cholinesterases
R. D. O'Brien

Contents of Other Volumes

VOLUME I

A General Introduction to the Field of Drug Design

E. J. Ariëns

Quantitative Structure-Activity Relationships in Drug Design

Corwin Hansch

Physicochemical Approaches to the Rational Development of New Drugs

J. K. Seydel

A Molecular Orbital Approach to Quantitative Drug Design

A. J. Wohl

Electronic Aspects of Drug Action

Roger L. Schnaare

The Role of Biopharmaceutics in the Design of Drug Products

John G. Wagner

Significance of Pharmacokinetics for Drug Design and the Planning of

Dosage Regimens

J. M. van Rossum

Author Index—Subject Index

VOLUME II

Modulation of Pharmacokinetics by Molecular Manipulation

E. J. Ariëns

Factors in the Design of Reversible and Irreversible Enzyme Inhibitors

Howard J. Schaeffer

The Design of Organophosphate and Carbamate Inhibitors of Cholinesterases

R. D. O'Brien

The Design of Reactivators for Irreversibly Blocked Acetylcholinesterase

I. B. Wilson and Harry C. Froede

Inhibition of Protein Biosynthesis: Its Significance in Drug Design

Arthur P. Grollman

Enzymes and Their Synthesis as a Target for Antibiotic Action

M. H. Richmond

The Rational Design of Antiviral Agents

Arthur P. Grollman and Susan B. Horwitz

Design of Penicillins

A. E. Bird and J. H. C. Nayler

The Design of Peptide Hormone Analogs

J. Rudinger

Recent Advances in the Design of Diuretics

George de Stevens

Design of Biologically Active Steroids

G. A. Overbeek, J. van der Vies, and J. de Visser

Rational Elements in the Development of Superior Neuromuscular Blocking Agents

M. Martin-Smith

The Design of Tumor-Inhibitory Alkylating Drugs

J. A. Stock

Author Index—Subject Index

VOLUME III

Microbial Conversion as a Tool in the Preparation of Drugs

R. Beukers, A. F. Marx, and M. H. J. Zuidweg

The Use of Linear Free Energy Parameters and Other Experimental Constants in Structure-Activity Studies

A. Verloop

Anticoagulants Structurally and Functionally Related to Vitamin K

*T. Kralt and V. Claassen*Design of β -Blocking Drugs*A. M. Barrett*

The Design of Biologically Active Acridines

Adrien Albert

The Design of Local Anesthetics

J. Büchi and X. Perlia

Design of Insect Chemosterilants

Ralph B. Turner

Molecular Approach for Designing Inhibitors to Enzymes Involved in Blood Clotting

L. Lorand and J. G. L. Nilsson

Author Index—Subject Index

VOLUME IV

Biopharmaceutics as a Basis for the Design of Drug Products

Leslie Z. Benet

Peroral Solid Dosage Forms with Prolonged Action

W. A. Ritschel

Parenteral Dosage Forms with Prolonged Action

W. A. Ritschel

Design of Topical Drug Products: Pharmaceuticals*Martin Katz***Design of Topical Drug Products: Biopharmaceutics***Boyd J. Poulsen***The Design of Sunscreen Preparations***Goswin W. van Ham and Wolfgang P. Herzog***Litholytic Agents: Preventive and Curative Drugs for Nephrolithiasis***George Kallistratos***The Design of Biologically Active Nucleosides***Alexander Bloch***The Design of Insecticidal Chlorohydrocarbon Derivatives***G. T. Brooks***Author Index—Subject Index****VOLUME V****Utilization of Operational Schemes for Analog Synthesis in Drug Design***John G. Topliss and Yvonne C. Martin***The Design of Enzyme Inhibitors: Transition State Analogs***R. N. Lindquist***Structure–Absorption–Distribution Relationships: Significance for Drug Design***Eric J. Lien***The Role of Charge-Transfer Processes in the Action of Bioactive Materials***Peter H. Doukas***Approaches to the Rational Combination of Antimetabolites for Cancer Chemotherapy***Gerald B. Grindey, Richard G. Moran, and William C. Werkheiser*

Physicochemical, Quantum Chemical, and Other Theoretical Techniques
for the Understanding of the Mechanism of Action of CNS Agents:
Psychoactive Drugs, Narcotics, and Narcotic Antagonists and Anesthetics
Joyce J. Kaufman and Walter S. Koski

Subject Index

88
93
124
126
126

IV. Theories of Protection
V. Chemical Radioprotective Agents
VI. Other Applications of Antiradiation Drugs
VII. The Future
References

Chapter 3. Rational Approach to Proteinase Inhibitors

Shosuke Okamoto and Akiko Hijioka

Contents

List of Contributors

Preface

Contents of Other Volumes

ix
xi
xiii

Chapter 1. Diphenhydramine Derivatives: Through Manipulation toward Design

A. F. Harms, W. Hespe, W. Th. Nauta, R. F. Rekker, H. Timmerman, and J. de Vries

I. Introduction. The Benzhydryl Moiety in Drugs	2
II. Review of the Synthetic Routes to Structures of the Diphenhydramine Type	3
III. The Phase of Manipulation. Classical Approaches to Arrive at Active Structures of the Diphenhydramine Type	24
IV. Detailed Analysis of the Conditions for Activity in Structures of the Diphenhydramine Type as a Basis for Rational Design	42
V. Metabolism of Diphenhydramines in Relation to Design	69
VI. Concluding Remarks	75
References	76

Chapter 2. The Design of Antiradiation Agents

Daniel L. Klayman and Edmund S. Copeland

I. Introduction	82
II. The Nature of Radiation Damage	82
III. Evaluation of Potential Antiradiation Agents	86

IV. Theories of Protection	88
V. Chemical Radioprotective Agents	93
VI. Other Applications of Antiradiation Drugs	124
VII. The Future	126
References	126

Chapter 3. Rational Approach to Proteinase Inhibitors

Shosuke Okamoto and Akiko Hijikata

I. Introduction	143
II. Lysine Homologs as Proteinase Inhibitors	145
III. Arginine Homologs as Proteinase Inhibitors	155
IV. Peptides as Proteinase Inhibitors	163
V. Coding, Decoding, and Noise in Proteolytic Reactions	166
References	168

Chapter 4. The Design of Organ-Imaging Radiopharmaceuticals

Raymond E. Counsell and Rodney D. Ice

I. Introduction	172
II. Essential Properties	173
III. Design Concepts	191
IV. Imaging Agents—Current Status	195
References	249

Chapter 5. Design of X-Ray Contrast Media

Hans-Joachim Herms and Volker Taenzer

I. The Uses of Radiographic Contrast Agents	263
II. Physical Basics	265
III. Chemistry of Contrast Agents	267
IV. Physicochemical Properties of Contrast Agents	275
V. Toxicology	276
VI. Pharmacology and Pharmacokinetics	281
VII. The Risks of X-Ray Contrast Diagnosis	288
VIII. New Drug Design	288
References	292

Chapter 6. **Agricultural Pesticides: Chemical and Physical Methods of Formulation**

G. S. Hartley

I. Introduction	298
II. Pesticides in the Immediate Environment	302
III. Systemic Pesticides in Agriculture	307
IV. Physical Formulation	325
V. Chemical Formulation	340
References	349

Subject Index

353

Chapter 1 Diphenhydramine Derivatives: Through Manipulation toward Design

*A. F. Harms, W. Hespe, W. Th. Nauta, R. F. Rekker,
H. Timmerman, and J. de Vries*

I. Introduction. The Benzhydryl Moiety in Drugs	2
II. Review of the Synthetic Routes to Structures of the Diphenhydramine Type	3
A. Introduction	3
B. Formation of the Ether Bond as the Final Reaction	14
C. Introduction of the Amino Function as the Final Reaction	17
D. Formation of Thio Ethers	22
E. Miscellaneous Reactions	22
III. The Phase of Manipulation. Classical Approaches to Arrive at Active Structures of the Diphenhydramine Type	24
A. Introduction. Profile of the Biological Activity of Diphenhydramine	24
B. Substitution in the Benzhydryl Moiety	24
C. Introduction of a Bridge in the Benzhydryl Moiety	31
D. Replacement of One Phenyl Group by Other Groups	32
E. Changes in the Oxyalkylamine Side Chain	34
F. Concluding Remarks	40
IV. Detailed Analysis of the Conditions for Activity in Structures of the Diphenhydramine Type as a Basis for Rational Design	42
A. Introduction	42
B. Ether Bond Stability	43
C. Base Function in the Molecule	47
D. Correlation of Ether Bond Stability and pK_a with Linear Free Energy Parameters	48
E. Some Other Physicochemical Parameters in Correlating Structure and Activity	50
F. Hansch's Approach: Multiple Regression Analysis (MRA)	53

G. Influence of Chirality on the Activity Pattern	54
H. Improved MRA	59
I. MRA of a Series of Diphenhydramines with the Nitrogen-atom Included in a Ring System	63
J. Concluding Remarks	65
V. Metabolism of Diphenhydramines in Relation to Design	69
A. Design and Absorption.	69
B. Design and Distribution	70
C. Design and Biotransformation	73
VI. Concluding Remarks	75
References	76

I. Introduction. The Benzhydryl Moiety in Drugs

It is a striking fact that among the great diversity of bioactive compounds there are many that have the diarylmethylene group as a common feature. Negwer (104) cites among 3326 structures with 13 or more carbon atoms, 302 drugs which can be construed as diphenylmethane derivatives. If one adds those structures in which one aryl nucleus is (partly) hydrogenated or one or both are replaced by other aromatic systems such as pyridyl and thienyl, the number is far higher.

Chemically there is a great variety in structures, ranging from simple diphenylmethane derivatives to compounds in which the diarylmethylene group is part of a (poly)cyclic ring system. The biological activities, too, cover a broad range. Tables I and II* may give an impression of the importance of the diarylmethylene group as a biofunctional moiety. In this chapter we will limit ourselves to the title compounds and some closely related structures.

In 1944 Rieveschl synthesized the 2-(dimethylamino)ethyl ether of diphenylmethanol (119), which compound was introduced as an antihistaminic under the name of diphenhydramine in 1945 (Benadryl, Fig. 1). Rieveschl probably based his work on an earlier structure (929F) found by Fournéau in 1933 to have antihistamine activity (40). The product was immediately successful and now, after almost 30 years, diphenhydramine is still one of the most widely used antihistaminics.

There were several reasons why this compound aroused our interest. Investigations which had been going on since the 1930s, had demonstrated that alkyl substitution considerably affects the physicochemical properties of, for instance, tetraphenylethanes which contain the diphenylmethyl group, just like diphenhydramine (19). After pharmacological investigations

* Of each type of compounds only a few examples are given.




Fig. 1. Diphenhydramine (from Rieveschl, 1944).


had shown that diphenhydramine possessed anticholinergic and local-anesthetic activity as well as antihistamine activity, we decided that it would be worthwhile to try to achieve compounds with greater specificity of action by adequate substitution such that the rigidity of the molecule and/or its charge distribution was modified. Already from the first series of compounds synthesized it became clear that within certain limits it was indeed possible to produce such an effect by introducing one or more alkyl substituents in one or both phenyl rings (103). Subsequently, systematic changes in the alkylene chain and the basic part of the molecule were studied (102).

In the following sections we shall first deal with the chemical routes available for the synthesis of diphenhydramine derivatives and then with their biological activities and the gradually unfolding relationships between structure and activity. In this way we hope to illustrate how a phase of molecular manipulation developed into one in which more rational attempts to design have become possible.

II. Review of the Synthetic Routes to Structures of the Diphenhydramine Type

A. INTRODUCTION

In this section we review the synthesis of amino ethers of the diphen-



hydramine type in which

A is either a (substituted) diphenylmethyl group, a (substituted) 5H-dibenzo[a,d]cyclohepten-5-yl group or an aza- analog of either of these groups;

X is O or S;

Alk is a lower alkylene group, which may be branched and/or carry hydroxyl groups, or be interrupted by an oxygen atom;

R¹ and R² are either hydrogen or lower alkyl or aralkyl groups, or form together with the nitrogen atom, or with the nitrogen and Alk, a heterocyclic ring.